Literature DB >> 19812053

APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Piya Lahiry1, Henian Cao, Matthew R Ban, Rebecca L Pollex, Mary Mamakeesick, Bernard Zinman, Stewart B Harris, Anthony J G Hanley, Murray W Huff, Philip W Connelly, Robert A Hegele.   

Abstract

Apolipoprotein (apo) C-I is a constituent of chylomicrons, very low density lipoprotein, and high density lipoprotein. The role of apo C-I in human metabolism is incompletely defined. We took advantage of a naturally occurring amino acid polymorphism that is present in aboriginal North Americans, namely apo C-I T45S. We assessed the hypothesis that metabolic traits, including obesity-related and lipoprotein-related traits, would differ between carriers and noncarriers of apo C-I T45S. A genotyping assay was developed for APOC1 T45S and genotypes were determined in a sample of 410 Canadian Oji-Cree subjects. The allele frequency of the apo C-I S45 allele was approximately 8% in this sample. We observed the apo C-I S45 allele was significantly associated with 1) lower percent body fat (P < 0.05), 2) lower waist circumference (P = 0.058), 3) lower serum leptin levels (P < 0.05), and 4) lower plasma apo C-I levels (P < 0.0001), using a newly developed ELISA-based method. Taken together, these results suggest that at the whole human phenotype level, apo C-I is associated with the complex metabolic trait of obesity as well as with serum leptin levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812053      PMCID: PMC2842156          DOI: 10.1194/jlr.P002014

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

1.  Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase.

Authors:  A K Soutar; C W Garner; H N Baker; J T Sparrow; R L Jackson; A M Gotto; L C Smith
Journal:  Biochemistry       Date:  1975-07-15       Impact factor: 3.162

Review 2.  Plasma lipoproteins: genetic influences and clinical implications.

Authors:  Robert A Hegele
Journal:  Nat Rev Genet       Date:  2009-01-13       Impact factor: 53.242

3.  Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

Authors:  I Lemieux; A Pascot; C Couillard; B Lamarche; A Tchernof; N Alméras; J Bergeron; D Gaudet; G Tremblay; D Prud'homme; A Nadeau; J P Després
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

4.  Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages.

Authors:  Marit Westerterp; Miranda Van Eck; Willeke de Haan; Erik H Offerman; Theo J C Van Berkel; Louis M Havekes; Patrick C N Rensen
Journal:  Atherosclerosis       Date:  2007-02-23       Impact factor: 5.162

5.  Correlation of a T45S variant of apolipoprotein C1 with elevated BMI in persons of American Indian and Mexican ancestries.

Authors:  R S Kasthuri; K R McMillan; C Flood-Urdangarin; S B Harvey; J T Wilson-Grady; G L Nelsestuen
Journal:  Int J Obes (Lond)       Date:  2007-02-20       Impact factor: 5.095

6.  Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo.

Authors:  Willeke de Haan; Ruud Out; Jimmy F P Berbée; Caroline C van der Hoogt; Ko Willems van Dijk; Theo J C van Berkel; Johannes A Romijn; J Wouter Jukema; Louis M Havekes; Patrick C N Rensen
Journal:  Biochem Biophys Res Commun       Date:  2008-11-06       Impact factor: 3.575

7.  Human apolipoprotein C-I expression in mice impairs learning and memory functions.

Authors:  Karlygash Abildayeva; Jimmy F P Berbée; Arjan Blokland; Paula J Jansen; Frans J Hoek; Onno Meijer; Dieter Lütjohann; Thomas Gautier; Thierry Pillot; Jan De Vente; Louis M Havekes; Frans C S Ramaekers; Folkert Kuipers; Patrick C N Rensen; Monique Mulder
Journal:  J Lipid Res       Date:  2007-12-26       Impact factor: 5.922

8.  Preliminary report on a case of apolipoproteins CI and CII deficiency.

Authors:  M F Dumon; M Clerc
Journal:  Clin Chim Acta       Date:  1986-06-30       Impact factor: 3.786

9.  Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome.

Authors:  Rachel L M van der Ham; Reza Alizadeh Dehnavi; Jimmy F P Berbée; Hein Putter; Albert de Roos; Johannes A Romijn; Patrick C N Rensen; Jouke T Tamsma
Journal:  Diabetes Care       Date:  2008-10-03       Impact factor: 17.152

10.  Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.

Authors:  Hao Li; Sally Wetten; Li Li; Pamela L St Jean; Ruchi Upmanyu; Linda Surh; David Hosford; Michael R Barnes; James David Briley; Michael Borrie; Natalie Coletta; Richard Delisle; Daniella Dhalla; Margaret G Ehm; Howard H Feldman; Luis Fornazzari; Serge Gauthier; Neil Goodgame; Danilo Guzman; Sandra Hammond; Paul Hollingworth; Ging-Yuek Hsiung; Joan Johnson; Devon D Kelly; Ron Keren; Andrew Kertesz; Karen S King; Simon Lovestone; Inge Loy-English; Paul M Matthews; Michael J Owen; Mary Plumpton; William Pryse-Phillips; Rab K Prinjha; Jill C Richardson; Ann Saunders; Andrew J Slater; Peter H St George-Hyslop; Sandra W Stinnett; Jina E Swartz; Rachel L Taylor; John Wherrett; Julie Williams; David P Yarnall; Rachel A Gibson; Michael C Irizarry; Lefkos T Middleton; Allen D Roses
Journal:  Arch Neurol       Date:  2007-11-12
View more
  8 in total

1.  Proteogenomic Review of the Changes in Primate apoC-I during Evolution.

Authors:  Donald Puppione; Julian P Whitelegge
Journal:  Front Biol (Beijing)       Date:  2013-10-02

2.  Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.

Authors:  Robert A Hegele
Journal:  J Lipid Res       Date:  2016-07-13       Impact factor: 5.922

3.  Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis.

Authors:  Catherine J McNeal; Subroto Chatterjee; Jennifer Hou; London S Worthy; Craig D Larner; Ronald D Macfarlane; Petar Alaupovic; Robert W Brocia
Journal:  Cardiovasc Res       Date:  2013-01-25       Impact factor: 10.787

4.  WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.

Authors:  Yannick Cyr; Hanny Wassef; Simon Bissonnette; Valerie Lamantia; Jean Davignon; May Faraj
Journal:  J Lipid Res       Date:  2016-04-03       Impact factor: 5.922

5.  Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1.

Authors:  Nicole E B Skinner; Matthew S Wroblewski; Julie A Kirihara; Gary L Nelsestuen; Elizabeth R Seaquist
Journal:  Diabetes Ther       Date:  2015-07-22       Impact factor: 2.945

Review 6.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

7.  Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.

Authors:  Michelle Hilbert; Peter Kuzman; Wolf C Mueller; Jürgen Meixensberger; Ulf Nestler
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

8.  Association analysis of dyslipidemia-related genes in diabetic nephropathy.

Authors:  Gareth J McKay; David A Savage; Christopher C Patterson; Gareth Lewis; Amy Jayne McKnight; Alexander P Maxwell
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.